Ukr.Biochem.J. 2019; Volume 91, Issue 1, Jan-Feb, pp. 74-79

doi: https://doi.org/10.15407/ubj91.01.074

Diagnostic significance of biochemical indicators of liver fibrogenesis in adolescents with obesity

22.01.2019   Uncategorized   No comments

O. V. Buznytska

Kharkіv Medical Academy of Postgraduate Education,
V. N. Karazin Kharkіv National University, Ukraine
e-mail: ebuznickaa@ukr.net; missbuzelena@gmail.com

Received: 27 September 2018; Accepted: 13 December 2018

Non-alcoholic fatty liver disease occurs in most obese people, the main pathway of which is the process of fibrogenesis. The aim of this work was to determine the potential biomarkers for early diagnosis of liver fibrogenesis in adolescents with obesity. The levels of liver fibrosis markers, such as fibronectin, collagen type IV, N-terminal propeptides and C-terminal telopeptides of type I collagen, were assessed with the use of IFA method in serum of 226 patients with obesity aged 8-18 years. A significant increase in levels of type IV collagen and fibronectin was observed in children with obesity (P < 0.05). As diagnostic criteria for fibrogenesis and fibrolysis, the levels of N-terminal propeptides and C-terminal telopeptides of type I collagen, respectively, were determined. The serum level of N-terminal propeptides of type I collagen significantly exceeds the normal values in all children with obesity compared to the control group (P < 0.05). The biochemical markers (type IV collagen, fibronectin, N-terminal propeptides and C-terminal telopeptides of type I collagen) were proven to have high diagnostic informative value in the early diagnosis of liver fibrogenesis in obese adolescents. It was shown that the signs of fibrosis in non-alcoholic fatty liver disease already occur at the stage of steatosis.

Keywords: , , , ,

References:

  1. Ivashkin VT. Diagnosis and treatment of non-alcoholic fatty liver disease. M.: MEDpress-inform, 2012. 436 p.
  2. Parkhomenko LK, Strashok LA, Eshchenko AV, Buznytskaya EV. Problems of diagnosis of non-alcoholic fatty liver disease in adolescence. Child Health. 2011;7(34):107-112.
  3. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am J Gastroenterol. 2012 Jun;107(6):811-26.  PubMed, CrossRef
  4. Della Corte C, Alisi A, Saccari A, De Vito R, Vania A, Nobili V. Nonalcoholic fatty liver in children and adolescents: an overview. J Adolesc Health. 2012 Oct;51(4):305-12. PubMed, CrossRef
  5. Polyzos SA, Mantzoros CS. Nonalcoholic fatty future disease. Metabolism. 2016 Aug;65(8):1007-16. PubMed, CrossRef
  6. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011 Dec;43(8):617-49. PubMed, CrossRef
  7. Yeloieva ZV , Strashok LA , Buznytska OV , Filonova TО, Shtrakh KV. Functional state of gepatobiliary system of children with obesity. Probl Uninterrupted Med Train Sci. 2017; 4: 37-42.
  8. Jayakumar S, Harrison SA, Loomba R. Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016 Jun;15(2):86-95.  PubMed, PubMedCentral
  9. Bloomgarden ZT. Second World Congress on the Insulin Resistance Syndrome: insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care. 2005 Jun;28(6):1518-23. PubMed
  10. Babak OYa, Kravchenko NA. Serum biomarkers and fibrotests in the diagnosis of liver fibrosis: disadvantages and prospects. Modern Gastroenterol. 2012;(3(65):71–80.
  11. Alkhouri N, Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism. 2016 Aug;65(8):1087-95.  PubMed, PubMedCentral, CrossRef
  12. Papagianni M, Sofogianni A, Tziomalos K. Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J Hepatol. 2015 Apr 8;7(4):638-48. PubMed, PubMedCentral, CrossRef
  13. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010 Sep;59(9):1265-9.  PubMed, CrossRef
  14. Al-Hamad D, Raman V. Metabolic syndrome in children and adolescents. Transl Pediatr. 2017 Oct;6(4):397-407.  PubMed, PubMedCentral, CrossRef
  15. Mantovani A, Zaza G, Byrne CD, Lonardo A, Zoppini G, Bonora E, Targher G. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism. 2018 Feb;79:64-76. PubMed, CrossRef
  16. O’Neill S, O’Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obes Rev. 2015 Jan;16(1):1-12. PubMed, CrossRef
  17. Cholongitas E, Senzolo M, Standish R, Marelli L, Quaglia A, Patch D, Dhillon AP, Burroughs AK. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol. 2006 May;125(5):710-21. PubMed, CrossRef
  18. Sanai FM, Keeffe EB. Liver biopsy for histological assessment: The case against. Saudi J Gastroenterol. 2010 Apr-Jun;16(2):124-32.  PubMed, PubMedCentral, CrossRef
  19. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12. PubMed, PubMedCentral, CrossRef
Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License.